Leishmania Major Protein Disulfide Isomerase As a Drug Target: Enzymatic and Functional Characterization

Overview

Journal Parasitol Res

Specialty Parasitology

Date 2011 Dec 14

PMID 22160278

Citations 13

Authors

Noureddine Ben Khalaf

Geraldine De Muylder

Hechmi Louzir

James McKerrow

Mehdi Chenik

Affiliations

Soon will be listed here.

Abstract

Leishmaniasis is a major health problem worldwide and tools available for their control are limited. Effective vaccines are still lacking, drugs are toxic and expensive, and parasites develop resistance to chemotherapy. In this context, new antimicrobials are urgently needed to control the disease in both human and animal. Here, we report the enzymatic and functional characterization of a Leishmania virulence factor, Leishmania major Protein disulfide isomerase (LmPDI) that could constitute a potential drug target. LmPDI possesses domain structure organization similar to other PDI family members (a, a', b, b' and c domains), and it displays the three enzymatic and functional activities specific of PDI family members: isomerase, reductase and chaperone. These results suggest that LmPDI plays a key role in assisting Leishmania protein folding via its capacity to catalyze formation, breakage, and rearrangement of disulfide bonds in nascent polypeptides. Moreover, Bacitracin, a reductase activity inhibitor, and Ribostamycin, a chaperone activity inhibitor, were tested in LmPDI enzymatic assays and versus Leishmania promastigote in vitro cultures and Leishmania amastigote multiplication inside infected THP-1-derived macrophages. Bacitracin inhibited both isomerase and reductase activities, while Ribostamycin had no effect on the chaperone activity. Interestingly, Bacitracin blocked in vitro promastigote growth as well as amastigote multiplication inside macrophages with EC(50) values of 39 μM. These results suggest that LmPDI may constitute an interesting target for the development of new anti-Leishmania drugs.

Citing Articles

Expression of Network Medicine-Predicted Genes in Human Macrophages Infected with .

Caixeta F, Martins V, Figueiredo A, Afonso L, Tieri P, Castiglione F Int J Mol Sci. 2024; 25(22).

PMID: 39596151 PMC: 11594204. DOI: 10.3390/ijms252212084.

Drug Discovery for Cutaneous Leishmaniasis: A Review of Developments in the Past 15 Years.

Corman H, McNamara C, Bakowski M Microorganisms. 2023; 11(12).

PMID: 38137989 PMC: 10745741. DOI: 10.3390/microorganisms11122845.

Mechanism of Erastin-Induced Ferroptosis in MDA-MB-231 Human Breast Cancer Cells: Evidence for a Critical Role of Protein Disulfide Isomerase.

Wang H, Wang P, Zhu B Mol Cell Biol. 2022; 42(6):e0052221.

PMID: 35499331 PMC: 9202373. DOI: 10.1128/mcb.00522-21.

A computer-aided approach to identify novel Leishmania major protein disulfide isomerase inhibitors for treatment of leishmaniasis.

Ben Khalaf N, Pham S, Romeo G, Abdelghany S, Intagliata S, Sedillo P J Comput Aided Mol Des. 2021; 35(3):297-314.

PMID: 33615401 DOI: 10.1007/s10822-021-00374-w.

Potential therapeutic targets shared between leishmaniasis and cancer.

Rashidi S, Fernandez-Rubio C, Manzano-Roman R, Mansouri R, Shafiei R, Ali-Hassanzadeh M Parasitology. 2021; 148(6):655-671.

PMID: 33536086 PMC: 10090780. DOI: 10.1017/S0031182021000160.

References

Padilla A, Noiva R, Lee N, Mohan K, Nakhasi H, Debrabant A . An atypical protein disulfide isomerase from the protozoan parasite Leishmania containing a single thioredoxin-like domain. J Biol Chem. 2002; 278(3):1872-8. DOI: 10.1074/jbc.M210322200. View

Chenik M, Lakhal S, Ben Khalef N, Zribi L, Louzir H, Dellagi K . Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites. Parasitology. 2006; 132(Pt 4):493-509. DOI: 10.1017/S0031182005009546. View

Kedzierski L, Sakthianandeswaren A, Curtis J, Andrews P, Junk P, Kedzierska K . Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem. 2009; 16(5):599-614. DOI: 10.2174/092986709787458489. View

Karamian M, Motazedian M, Mehrabani D, Gholami K . Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B. Parasitol Res. 2007; 101(5):1431-4. DOI: 10.1007/s00436-007-0649-x. View

Krauth-Siegel R, Comini M . Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim Biophys Acta. 2008; 1780(11):1236-48. DOI: 10.1016/j.bbagen.2008.03.006. View

Mussi S, Fernandes A, Ferreira L . Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res. 2007; 100(6):1221-6. DOI: 10.1007/s00436-006-0394-6. View

Brotherton M, Racine G, Foucher A, Drummelsmith J, Papadopoulou B, Ouellette M . Analysis of stage-specific expression of basic proteins in Leishmania infantum. J Proteome Res. 2010; 9(8):3842-53. DOI: 10.1021/pr100048m. View

Handman E . Cell biology of Leishmania. Adv Parasitol. 1999; 44:1-39. DOI: 10.1016/s0065-308x(08)60229-8. View

Ait-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D . Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res. 2011; 109(5):1225-32. DOI: 10.1007/s00436-011-2555-5. View

10.

Krauth-Siegel R, Inhoff O . Parasite-specific trypanothione reductase as a drug target molecule. Parasitol Res. 2003; 90 Suppl 2:S77-85. DOI: 10.1007/s00436-002-0771-8. View

11.

Karala A, Ruddock L . Bacitracin is not a specific inhibitor of protein disulfide isomerase. FEBS J. 2010; 277(11):2454-62. DOI: 10.1111/j.1742-4658.2010.07660.x. View

12.

Zhang R, Shang L, Jin H, Ma C, Wu Y, Liu Q . In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Parasitol Res. 2010; 107(2):475-9. DOI: 10.1007/s00436-010-1906-y. View

13.

McNicoll F, Drummelsmith J, Muller M, Madore E, Boilard N, Ouellette M . A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics. 2006; 6(12):3567-81. DOI: 10.1002/pmic.200500853. View

14.

Martin J, Langer T, Boteva R, Schramel A, Horwich A, Hartl F . Chaperonin-mediated protein folding at the surface of groEL through a 'molten globule'-like intermediate. Nature. 1991; 352(6330):36-42. DOI: 10.1038/352036a0. View

15.

Heras B, Shouldice S, Totsika M, Scanlon M, Schembri M, Martin J . DSB proteins and bacterial pathogenicity. Nat Rev Microbiol. 2009; 7(3):215-25. DOI: 10.1038/nrmicro2087. View

16.

Mouray E, Moutiez M, Girault S, Sergheraert C, Florent I, Grellier P . Biochemical properties and cellular localization of Plasmodium falciparum protein disulfide isomerase. Biochimie. 2006; 89(3):337-46. DOI: 10.1016/j.biochi.2006.11.001. View

17.

Santos C, Stolf B, Takemoto P, Amanso A, Lopes L, Souza E . Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of Leishmania chagasi promastigotes by macrophages. J Leukoc Biol. 2009; 86(4):989-98. DOI: 10.1189/jlb.0608354. View

18.

Hong B, Soong L . Identification and enzymatic activities of four protein disulfide isomerase (PDI) isoforms of Leishmania amazonensis. Parasitol Res. 2007; 102(3):437-46. PMC: 2745823. DOI: 10.1007/s00436-007-0784-4. View

19.

Shakya N, Sane S, Gupta S . Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv. Parasitol Res. 2011; 108(4):793-800. DOI: 10.1007/s00436-010-2230-2. View

20.

Holmgren A . Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action. J Biol Chem. 1979; 254(18):9113-9. View